Evotec Results Presentation Deck

in € m¹) evotec Revenues PAGE 11 Strong performance across all business lines Segment information H1 2021- Evotec SE and subsidiaries Gross margin • R&D expenses • SG&A expenses Impairment of intangible assets and goodwill • Other op. income (expenses), net Operating result Adjusted EBITDA²) Inter- EVT EVT segment Execute Innovate elimination 279.5 57.3 (65.5) 19.0% (1.0) (37.2) 11.4 26.2 51.9 16.3% (40.5) (9.2) (0.7) 23.2 (17.9) (15.7) 6.0 T Evotec Group 271.3 20.8% (35.4) (46.4) (0.7) 34.5 8.3 36.2 . Both segments show very strong performance versus Q1 • EVT Execute: 18% growth including inter- segment revenues implies accelerated demand for integrated offering EVOIR&D; 15% growth of external revenues driven by strong base business demand • EVT Innovate: 27% growth driven by precision medicine platforms Adjusted Group EBITDA influenced by end of Sanofi subsidy, unfavourable fx effects, increased R&D investments and planned capacity expansion, reflected by growing SG&A ¹) Differences may occur due to rounding 2) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

View entire presentation